Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD37-Siglec6 bispecific CAR-T
- Development stage
- Preclinical
- Lead developer
- Hangzhou Medical College
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD37-Siglec6 bispecific CAR-T is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy designed to simultaneously target CD37 and Sialic acid-binding Ig-like lectin 6 (Siglec-6), two antigens highly expressed on leukemia stem cell (LSC) subpopulations in acute myeloid leukemia (AML). Developed as an academic research project at Hangzhou Medical College, this therapy aims to overcome challenges in relapsed/refractory pediatric AML, such as antigen heterogeneity and off-tumor toxicity. The CAR constructs are delivered via lentiviral vectors. Preclinical studies in NSG mouse xenograft models have demonstrated that the bispecific approach enhances anti-leukemic activity, improves T-cell persistence, and reduces exhaustion compared to single-target CAR-T cells, while maintaining a favorable safety profile regarding normal hematopoiesis.
- Other names
- CD37-Siglec6 CAR-TCD-37-Siglec6 CAR-TCD 37-Siglec6 CAR-Tbispecific CD37-Siglec6 CAR-T
02
Targets
SIGLEC6 (Siglec-6)CD37
Beyond the preview
Go deeper on CD37-Siglec6 bispecific CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD37-Siglec6 bispecific CAR-T.